-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Initiates Coverage On MapLight Therapeutics with Overweight Rating, Announces Price Target of $34

Benzinga·11/21/2025 12:19:16
Listen to the news
Morgan Stanley analyst Sean Laaman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Overweight rating and announces Price Target of $34.